This collaborative framework will allow us to offer patients promising new stem cell therapies and treatments.
MIAMI (PRWEB) February 17, 2015
Regenestem Network, a subsidiary of the Global Stem Cells Group, announced plans to join Charles Mahl, M.D. to open a Regenestem Health Clinic in the historic Westin Colonnade in Coral Gables, Florida. The state-of-the-art clinic will serve as the flagship center for the Regenestem Network and U.S. headquarters for stem cell training courses and patient treatments.
Mahl, a specialist in regenerative medicine, preventive aging medicine and pain therapy, is a member of the Global Stem Cells Group Advisory Board. His recent plans to open a clinic in the spectacular landmark hotel in central Miami lead Mahl to invite Global Stem Cells Group co-founder and Regenestem CEO Ricardo DeCubas to collaborate.
The Westin Colonnade clinic will offer pain, anti-aging and aesthetic regenerative medicine treatments and therapies.
The Regenestem Network is a global family of premier regenerative medicine providers all sharing the same mission—to bring the latest in stem cell medicine to patients worldwide. The Regenestem Network is comprised of physicians, medical professionals, researchers, teachers and regenerative medicine product development specialists.
“Regenestem’s commitment to helping improve the quality of life for patients through stem cell therapies makes it a model I wanted to incorporate into the clinic,” Mahl says. “This collaborative framework will allow us to offer patients promising new stem cell therapies and treatments.”
The clinic’s location within the historic Coral Gables Westin Colonnade in central Miami will welcome patients from across the U.S., Canada, and worldwide. Located just five minutes from the University of Miami, the iconic neoclassical hotel built in the early 20th century that originally served as the offices for Coral Gables’ intellectual founder George Merrick now serves as a 157-room hotel and hosts a mix of offices and retail space.
According to DeCubas, the clinic will make pain management, anti-aging and aesthetic regenerative medicine treatments readily available to physicians and patients in a clinical setting.
“We could not be more pleased or gratified to announce this new shared path of medical and scientific promise with Dr. Mahl and the Coral Gables Community,” DeCubas says.
“This opens new possibilities for discovery and treatments, and we are proud to work alongside Dr. Mahl to grow Regenestem Health into a cornerstone of patient care that will serve the community for years to come.”
The clinic is tentatively scheduled to open March 1, 2015. For more information, visit the Global Stem Cells Group website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.
About Charles Mahl, M.D.:
Charles F. Mahl, M.D. is a Miami-based expert in regenerative medicine, preventive aging and pain therapies. His expertise includes prolotherapy, platelet rich plasma injections and stem cell therapies for a variety of painful orthopedic conditions and injuries involving but not limited to the back, sacroiliac joints, hips, knees, shoulders and neck. He is also eminently qualified to perform stem cell therapies on the eyes due to his background as a vitreo-retinal surgeon prior to becoming interested in regenerative medicine and dedicating his medical career to this field.
A member of the Global Stem Cells Group Scientific Advisory Board, Mahl sees stem cells as medicine’s new frontier, offering unlimited possibilities for easing and eliminating many forms of disease and injury-related pain. He is a member of the Global Stem Cells Group Advisory Board and is licensed to practice medicine in Florida. Mahl is Board Certified in Integrative Medicine and has completed multiple fellowships in Age Management Mediciine. He spent more than two years in a mentorship program for prolotherapy and regenerative injection medicine with Alvin Stein, M.D., a relationship that continues to this day.
About the Regenestem Network:
The Regenestem Network, is a division of the Global Stem Cells Group, Inc., a worldwide collaborative of premier regenerative medicine providers with a singular mission—to bring the latest in stem cell medicine to patients on a global scale. The Regenestem Network is comprised of physicians, medical professionals, researchers, teachers and regenerative medicine product development specialists.
Regenestem provides stem cell treatments and products for a variety of diseases and conditions including arthritis, autism, chronic obstructive pulmonary disease (COPD), diabetes and multiple sclerosis at various facilities worldwide. Each Regenestem clinic offers an international staff experienced in administering the leading cellular therapies available.
Regenestem is certified for the medical tourism market, and staff physicians are board-certified or board-eligible. Regenestem clinics provide services in more than 10 specialties, attracting patients from the United States and around the world.
Regenestem is an international medical practice association committed to researching and producing comprehensive stem cell treatments for patients worldwide. Having assembled a highly qualified staff of medical specialists—professionals trained in the latest cutting-edge techniques in cellular medicine—Regenestem continues to be a leader in delivering the latest protocols in the adult stem cell arena.
About the Global Stem Cell Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.